Antigen presenting cell/ tumor cell fusion vaccines for cancer immunotherapy

References

• Sims RB. Development of sipuleucel-T: autologous cellular immunotherapy for the treatment of metastatic castrate resistant prostate cancer. Vaccine 2012; 30:4394 - 7; http://dx.doi.org/10.1016/j.vaccine.2011.11.058; PMID: 22122856
   PubMed Web of Science ®Google Scholar
• Guo Y, Wu M, Chen H, Wang X, Liu G, Li G, et al. Effective tumor vaccine generated by fusion of hepatoma cells with activated B cells. Science 1994; 263:518 - 20; http://dx.doi.org/10.1126/science.7507262; PMID: 7507262
   PubMed Web of Science ®Google Scholar
• Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002; 3:991 - 8; http://dx.doi.org/10.1038/ni1102-991; PMID: 12407406
   PubMed Web of Science ®Google Scholar
• Gong J, Chen D, Kashiwaba M, Kufe D. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat Med 1997; 3:558 - 61; http://dx.doi.org/10.1038/nm0597-558; PMID: 9142127
   PubMed Web of Science ®Google Scholar
• Wang J, Saffold S, Cao X, Krauss J, Chen W. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines. J Immunol 1998; 161:5516 - 24; PMID: 9820528
   PubMed Web of Science ®Google Scholar
• Gong J, Koido S, Chen D, Tanaka Y, Huang L, Avigan D, et al. Immunization against murine multiple myeloma with fusions of dendritic and plasmacytoma cells is potentiated by interleukin 12. Blood 2002; 99:2512 - 7; http://dx.doi.org/10.1182/blood.V99.7.2512; PMID: 11895787
   PubMed Web of Science ®Google Scholar
• Chen D, Xia J, Tanaka Y, Chen H, Koido S, Wernet O, et al. Immunotherapy of spontaneous mammary carcinoma with fusions of dendritic cells and mucin 1-positive carcinoma cells. Immunology 2003; 109:300 - 7; http://dx.doi.org/10.1046/j.1365-2567.2003.01656.x; PMID: 12757626
   PubMed Web of Science ®Google Scholar
• Siders WM, Vergilis KL, Johnson C, Shields J, Kaplan JM. Induction of specific antitumor immunity in the mouse with the electrofusion product of tumor cells and dendritic cells. Mol Ther 2003; 7:498 - 505; http://dx.doi.org/10.1016/S1525-0016(03)00044-3; PMID: 12727113
   PubMed Web of Science ®Google Scholar
• Xia J, Tanaka Y, Koido S, Liu C, Mukherjee P, Gendler SJ, et al. Prevention of spontaneous breast carcinoma by prophylactic vaccination with dendritic/tumor fusion cells. J Immunol 2003; 170:1980 - 6; PMID: 12574367
   PubMed Web of Science ®Google Scholar
• Iinuma T, Homma S, Noda T, Kufe D, Ohno T, Toda G. Prevention of gastrointestinal tumors based on adenomatous polyposis coli gene mutation by dendritic cell vaccine. J Clin Invest 2004; 113:1307 - 17; PMID: 15124022
   PubMed Web of Science ®Google Scholar
• Suzuki T, Fukuhara T, Tanaka M, Nakamura A, Akiyama K, Sakakibara T, et al. Vaccination of dendritic cells loaded with interleukin-12-secreting cancer cells augments in vivo antitumor immunity: characteristics of syngeneic and allogeneic antigen-presenting cell cancer hybrid cells. Clin Cancer Res 2005; 11:58 - 66; PMID: 15671528
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Koido S, Ohana M, Liu C, Gong J. Induction of impaired antitumor immunity by fusion of MHC class II-deficient dendritic cells with tumor cells. J Immunol 2005; 174:1274 - 80; PMID: 15661883
   PubMed Web of Science ®Google Scholar
• Savai R, Schermuly RT, Schneider M, Pullamsetti SS, Grimminger F, Seeger W, et al. Hybrid-primed lymphocytes and hybrid vaccination prevent tumor growth of lewis lung carcinoma in mice. J Immunother 2006; 29:175 - 87; http://dx.doi.org/10.1097/01.cji.0000197096.38476.fc; PMID: 16531818
   PubMedGoogle Scholar
• Yasuda T, Kamigaki T, Kawasaki K, Nakamura T, Yamamoto M, Kanemitsu K, et al. Superior anti-tumor protection and therapeutic efficacy of vaccination with allogeneic and semiallogeneic dendritic cell/tumor cell fusion hybrids for murine colon adenocarcinoma. Cancer Immunol Immunother 2007; 56:1025 - 36; http://dx.doi.org/10.1007/s00262-006-0252-5; PMID: 17131118
   PubMed Web of Science ®Google Scholar
• Takeda A, Homma S, Okamoto T, Kufe D, Ohno T. Immature dendritic cell/tumor cell fusions induce potent antitumour immunity. Eur J Clin Invest 2003; 33:897 - 904; http://dx.doi.org/10.1046/j.1365-2362.2003.01194.x; PMID: 14511362
   PubMed Web of Science ®Google Scholar
• Gong J, Koido S, Kato Y, Tanaka Y, Chen D, Jonas A, et al. Induction of anti-leukemic cytotoxic T lymphocytes by fusion of patient-derived dendritic cells with autologous myeloblasts. Leuk Res 2004; 28:1303 - 12; http://dx.doi.org/10.1016/j.leukres.2004.03.018; PMID: 15475072
   PubMed Web of Science ®Google Scholar
• Raje N, Hideshima T, Davies FE, Chauhan D, Treon SP, Young G, et al. Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma. Br J Haematol 2004; 125:343 - 52; http://dx.doi.org/10.1111/j.1365-2141.2004.04929.x; PMID: 15086415
   PubMed Web of Science ®Google Scholar
• Klammer M, Waterfall M, Samuel K, Turner ML, Roddie PH. Fusion hybrids of dendritic cells and autologous myeloid blasts as a potential cellular vaccine for acute myeloid leukaemia. Br J Haematol 2005; 129:340 - 9; http://dx.doi.org/10.1111/j.1365-2141.2005.05477.x; PMID: 15842657
   PubMed Web of Science ®Google Scholar
• Imura K, Ueda Y, Hayashi T, Itoh T, Shimizu K, Tamai H, et al. Induction of cytotoxic T lymphocytes against human cancer cell lines using dendritic cell-tumor cell hybrids generated by a newly developed electrofusion technique. Int J Oncol 2006; 29:531 - 9; PMID: 16865268
   PubMed Web of Science ®Google Scholar
• Rosenblatt J, Wu Z, Vasir B, Zarwan C, Stone R, Mills H, et al. Generation of tumor-specific T lymphocytes using dendritic cell/tumor fusions and anti-CD3/CD28. J Immunother 2010; 33:155 - 66; http://dx.doi.org/10.1097/CJI.0b013e3181bed253; PMID: 20145548
   PubMed Web of Science ®Google Scholar
• Trefzer U, Weingart G, Chen Y, Herberth G, Adrian K, Winter H, et al. Hybrid cell vaccination for cancer immune therapy: first clinical trial with metastatic melanoma. Int J Cancer 2000; 85:618 - 26; http://dx.doi.org/10.1002/(SICI)1097-0215(20000301)85:5<618::AID-IJC4>3.0.CO;2-Z; PMID: 10699939
   PubMed Web of Science ®Google Scholar
• Krause SW, Neumann C, Soruri A, Mayer S, Peters JH, Andreesen R. The treatment of patients with disseminated malignant melanoma by vaccination with autologous cell hybrids of tumor cells and dendritic cells. J Immunother 2002; 25:421 - 8; http://dx.doi.org/10.1097/00002371-200209000-00006; PMID: 12218780
   PubMed Web of Science ®Google Scholar
• Märten A, Renoth S, Heinicke T, Albers P, Pauli A, Mey U, et al. Allogeneic dendritic cells fused with tumor cells: preclinical results and outcome of a clinical phase I/II trial in patients with metastatic renal cell carcinoma. Hum Gene Ther 2003; 14:483 - 94; http://dx.doi.org/10.1089/104303403321467243; PMID: 12691613
   PubMed Web of Science ®Google Scholar
• Barbuto JA, Ensina LF, Neves AR, Bergami-Santos P, Leite KR, Marques R, et al. Dendritic cell-tumor cell hybrid vaccination for metastatic cancer. Cancer Immunol Immunother 2004; 53:1111 - 8; http://dx.doi.org/10.1007/s00262-004-0551-7; PMID: 15185011
   PubMed Web of Science ®Google Scholar
• Trefzer U, Herberth G, Wohlan K, Milling A, Thiemann M, Sherev T, et al. Vaccination with hybrids of tumor and dendritic cells induces tumor-specific T-cell and clinical responses in melanoma stage III and IV patients. Int J Cancer 2004; 110:730 - 40; http://dx.doi.org/10.1002/ijc.20191; PMID: 15146563
   PubMed Web of Science ®Google Scholar
• Avigan D, Vasir B, Gong J, Borges V, Wu Z, Uhl L, et al. Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses. Clin Cancer Res 2004; 10:4699 - 708; http://dx.doi.org/10.1158/1078-0432.CCR-04-0347; PMID: 15269142
   PubMed Web of Science ®Google Scholar
• Trefzer U, Herberth G, Wohlan K, Milling A, Thiemann M, Sharav T, et al. Tumour-dendritic hybrid cell vaccination for the treatment of patients with malignant melanoma: immunological effects and clinical results. Vaccine 2005; 23:2367 - 73; http://dx.doi.org/10.1016/j.vaccine.2005.01.081; PMID: 15755630
   PubMed Web of Science ®Google Scholar
• Avigan DE, Vasir B, George DJ, Oh WK, Atkins MB, McDermott DF, et al. Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma. J Immunother 2007; 30:749 - 61; http://dx.doi.org/10.1097/CJI.0b013e3180de4ce8; PMID: 17893567
   PubMed Web of Science ®Google Scholar
• Rosenblatt J, Vasir B, Uhl L, Blotta S, Macnamara C, Somaiya P, et al. Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma. Blood 2011; 117:393 - 402; http://dx.doi.org/10.1182/blood-2010-04-277137; PMID: 21030562
   PubMed Web of Science ®Google Scholar
• Moviglia GA. Development of tumor B-cell lymphocyte hybridoma (TBH) autovaccination. Results of a phase I-II clinical trial. Transfus Sci 1996; 17:643 - 9; PMID: 10168565
   PubMedGoogle Scholar
• Kugler A, Seseke F, Thelen P, Kallerhoff M, Müller GA, Stuhler G, et al. Autologous and allogenic hybrid cell vaccine in patients with metastatic renal cell carcinoma. Br J Urol 1998; 82:487 - 93; http://dx.doi.org/10.1046/j.1464-410X.1998.00794.x; PMID: 9806175
   PubMedGoogle Scholar
• Newton DA, Acierno PM, Metts MC, Baron PL, Brescia FJ, Gattoni-Celli S. Semiallogeneic cancer vaccines formulated with granulocyte-macrophage colony-stimulating factor for patients with metastatic gastrointestinal adenocarcinomas: a pilot phase I study. J Immunother 2001; 24:19 - 26; http://dx.doi.org/10.1097/00002371-200101000-00003; PMID: 11211145
   PubMedGoogle Scholar
• Dunnion DJ, Cywinski AL, Tucker VC, Murray AK, Rickinson AB, Coulie P, et al. Human antigen-presenting cell/tumour cell hybrids stimulate strong allogeneic responses and present tumour-associated antigens to cytotoxic T cells in vitro. Immunology 1999; 98:541 - 50; http://dx.doi.org/10.1046/j.1365-2567.1999.00912.x; PMID: 10594686
   PubMedGoogle Scholar
• Mohamed YS, Dunnion D, Teobald I, Walewska R, Browning MJ. Long-lived fusions of human haematological tumour cells and B-lymphoblastoid cells induce tumour antigen-specific cytotoxic T-cell responses in vitro. Immunobiology 2012; 217:719 - 29; http://dx.doi.org/10.1016/j.imbio.2011.12.001; PMID: 22305004
   PubMedGoogle Scholar
• Mohamed YS, Dunnion D, Teobald I, Walewska R, Browning MJ. In vitro evaluation of human hybrid cell lines generated by fusion of B-lymphoblastoid cells and ex vivo tumour cells as candidate vaccines for haematological malignancies. Vaccine 2012; 30:6578 - 87; http://dx.doi.org/10.1016/j.vaccine.2012.08.032; PMID: 22939910
   PubMedGoogle Scholar
• Edwards PA, Smith CM, Neville AM, O’Hare MJ. A human-hybridoma system based on a fast-growing mutant of the ARH-77 plasma cell leukemia-derived line. Eur J Immunol 1982; 12:641 - 8; http://dx.doi.org/10.1002/eji.1830120804; PMID: 7140810
   PubMedGoogle Scholar
• Heslop HE, Slobod KS, Pule MA, Hale GA, Rousseau A, Smith CA, et al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 2010; 115:925 - 35; http://dx.doi.org/10.1182/blood-2009-08-239186; PMID: 19880495
   PubMed Web of Science ®Google Scholar
• Warren EH, Fujii N, Akatsuka Y, Chaney CN, Mito JK, Loeb KR, et al. Therapy of relapsed leukemia after allogeneic hematopoietic cell transplantation with T cells specific for minor histocompatibility antigens. Blood 2010; 115:3869 - 78; http://dx.doi.org/10.1182/blood-2009-10-248997; PMID: 20071660
   PubMed Web of Science ®Google Scholar
• Montagna D, Turin I, Schiavo R, Montini E, Zaffaroni N, Villa R, et al. Feasibility and safety of adoptive immunotherapy with ex vivo-generated autologous, cytotoxic T lymphocytes in patients with solid tumor. Cytotherapy 2012; 14:80 - 90; http://dx.doi.org/10.3109/14653249.2011.610303; PMID: 21942841
   PubMed Web of Science ®Google Scholar
• Savai R, Schermuly RT, Pullamsetti SS, Schneider M, Greschus S, Ghofrani HA, et al. A combination hybrid-based vaccination/adoptive cellular therapy to prevent tumor growth by involvement of T cells. Cancer Res 2007; 67:5443 - 53; http://dx.doi.org/10.1158/0008-5472.CAN-06-3677; PMID: 17545626
   PubMedGoogle Scholar